Zentalis Pharmaceuticals (ZNTL) Competitors $1.81 +0.02 (+1.12%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.50%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. UPB, CGEM, OPT, AKBA, PGEN, ANAB, MAZE, TRVI, SAGE, and MNMDShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Upstream Bio (UPB), Cullinan Therapeutics (CGEM), Opthea (OPT), Akebia Therapeutics (AKBA), Precigen (PGEN), AnaptysBio (ANAB), Maze Therapeutics (MAZE), Trevi Therapeutics (TRVI), Sage Therapeutics (SAGE), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Upstream Bio Cullinan Therapeutics Opthea Akebia Therapeutics Precigen AnaptysBio Maze Therapeutics Trevi Therapeutics Sage Therapeutics Mind Medicine (MindMed) Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Does the media refer more to ZNTL or UPB? In the previous week, Zentalis Pharmaceuticals had 7 more articles in the media than Upstream Bio. MarketBeat recorded 9 mentions for Zentalis Pharmaceuticals and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.84 beat Zentalis Pharmaceuticals' score of 0.74 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher valuation and earnings, ZNTL or UPB? Upstream Bio has lower revenue, but higher earnings than Zentalis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$40.56M3.01-$292.19M-$2.49-0.69Upstream Bio$2.37M155.49N/AN/AN/A Does the MarketBeat Community believe in ZNTL or UPB? Zentalis Pharmaceuticals received 58 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 62.00% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZentalis PharmaceuticalsOutperform Votes6262.00% Underperform Votes3838.00% Upstream BioOutperform Votes4100.00% Underperform VotesNo Votes Is ZNTL or UPB more profitable? Upstream Bio's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -43.91% -34.96% Upstream Bio N/A N/A N/A Do analysts prefer ZNTL or UPB? Zentalis Pharmaceuticals currently has a consensus target price of $8.24, suggesting a potential upside of 380.73%. Upstream Bio has a consensus target price of $56.50, suggesting a potential upside of 722.42%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryUpstream Bio beats Zentalis Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Remove Ads Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.22M$6.93B$5.64B$8.00BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-0.697.1923.1618.89Price / Sales3.01223.90384.1492.98Price / CashN/A65.6738.1634.64Price / Book0.286.456.904.30Net Income-$292.19M$141.90M$3.20B$247.06M7 Day Performance-10.21%-3.49%-1.69%-0.62%1 Month Performance-17.15%-5.92%2.68%-4.26%1 Year Performance-89.12%-7.90%10.20%0.61% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.9649 of 5 stars$1.81+1.1%$8.24+355.5%-88.2%$128.99M$40.56M-0.73160Earnings ReportAnalyst ForecastNews CoverageUPBUpstream BioN/A$9.87+2.7%$56.50+472.4%N/A$529.44M$2.37M0.0038Positive NewsCGEMCullinan Therapeutics2.1633 of 5 stars$9.03+2.7%$32.86+263.9%-53.2%$528.37MN/A-3.1830Positive NewsOPTOpthea0.7043 of 5 stars$3.41+7.1%$12.00+252.4%-12.8%$524.07M$87,666.000.008Analyst DowngradeShort Interest ↑Analyst RevisionNews CoverageGap UpAKBAAkebia Therapeutics3.5341 of 5 stars$2.40+6.2%$6.75+181.3%-13.8%$523.63M$169.88M-10.43430PGENPrecigen3.5374 of 5 stars$1.78-1.1%$7.00+293.3%+13.1%$521.31M$3.96M-3.24190Gap UpANABAnaptysBio2.9778 of 5 stars$16.51-1.3%$35.11+112.7%-12.8%$506.31M$91.28M-2.72100Buyback AnnouncementHigh Trading VolumeMAZEMaze TherapeuticsN/A$11.49+4.5%$25.67+123.4%N/A$503.00M$167.50M0.00121TRVITrevi Therapeutics3.6496 of 5 stars$6.54-3.1%$15.94+143.7%+88.2%$502.70MN/A-14.8620Short Interest ↑High Trading VolumeSAGESage Therapeutics2.9875 of 5 stars$8.02+3.9%$8.81+9.9%-54.5%$493.08M$41.24M-1.22690Positive NewsMNMDMind Medicine (MindMed)2.3985 of 5 stars$6.47+1.9%$25.11+288.1%-32.3%$487.63MN/A-2.8640Insider TradeAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies UPB Competitors CGEM Competitors OPT Competitors AKBA Competitors PGEN Competitors ANAB Competitors MAZE Competitors TRVI Competitors SAGE Competitors MNMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZNTL Stock Free ZNTL Stock Alerts